Handelsbanken Fonder
ARQT icon

Handelsbanken Fonder’s Arcutis Biotherapeutics ARQT Stock Holding History

Handelsbanken Fonder’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
43,800
+2,500
+6% +$58.2K ﹤0.01% 1069
2026
Q1 		$973K Buy
41,300
+7,000
+20% +$179K ﹤0.01% 1054
2025
Q4 		$996K Buy
+34,300
New +$878K ﹤0.01% 1027

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Handelsbanken Fonder's ARQT Position: Q2 2026 in Review

Handelsbanken Fonder increased its Arcutis Biotherapeutics (ARQT) stake by 6.1% in Q2 2026, buying an estimated $58.2K and bringing the position to 43,800 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1069.

Handelsbanken Fonder first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Handelsbanken Fonder held 43,800 shares of Arcutis Biotherapeutics worth $1.15M as of Q2 2026.
  • Handelsbanken Fonder bought 2,500 Arcutis Biotherapeutics shares in Q2 2026, an estimated $58.2K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1069 holding.
  • Handelsbanken Fonder first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.